From the Neogene website, their abstract presenting what needs to be done, the four bullet points below:
Copy/paste link:
https://www.neogene.com/staging/wp-content/uploads/2022/04/Keystone-2022-TGFBR2-KO-

TP53-R175H-TCR-poster-final-edit.pdf
>> • TGFBR2 KO TCR-edited T cells can be efficiently
generated using multiplexed CRISPR-Cas9 engineering.
• TGF-β signaling is almost completely disrupted
suggesting that TGFBR2 KO is very efficient.
• TGFBR2 KO T cells are resistant to TGF-β-mediated
immunosuppression as shown by enhanced serial
killing, long-term proliferation and cytokine production.
• Our next goal is to assess the pre-clinical safety and
potency of TP53 R175H TCR KI TGFBR2 KO T cell
products for subsequent clinical application. <<

NEOGENE is the firm that the NCI is also in CRADA for TCR-T, but using CRSPR transcription. They have a ways to go, including pre-clinical work in potency and safety (with CRSPR having a reputation for unintended, random changes to the human genome!). I am sure that Dr. Drew knows about their CRADA since DREW and the NCI talk frequently. Then again, remember Dr. Drew's slide and talk about SB -- simplicity, economic. Assuming that neoantigen targeting IS THE NCI's answer to solid cancers, I suggest the bar will be set high by Alaunos by the time Neogene/AZN is in clinical trials.

Interesting to read that PACT sold their out of their $50million South San Francisco lab. They thought they would be taking in tumor/blood samples, then sending back infusion bags all over the country. And Helen said SB/TCR-T will be bedside therapy in her 1Q21 cc! Did you see the writing on the wall, PACT? Poof.